Stereotaxic imaging (STXS) and Abbott’s combine techniques into integrated procedures for the treatment of patients with arrhythmias
stereoscopic (NYSE:), the leading and world-leading manufacturer of minimally invasive endovascular surgical robots, today announced that the first patients have been successfully treated using Abbott’s EnSite™ X EP System with Robotic Magnetic Navigation System.
The combination of Abbott’s pioneering cardiac mapping system with advanced stereotaxic focus robotic technology brings highly detailed real-time diagnostic information with unprecedented accuracy and stability for robots during treatment delivery. The integration of these technologies was announced at Heart Rhythm 2023. The first integrated procedures were successfully performed by Dr. Seng Shin Yap and Dr. Tamas Selye-Turok at Erasmus Medical Center in Rotterdam, Netherlands, and Dr. Burkhard Högel at Marienhaus St. Elisabeth Hospital in Neuwied, Germany.
“Combining advanced mapping with the accuracy and safety of robots helps provide the best treatment for patients and improve workflow for doctors,” said Dr. Seng Shin Yap. “EnSite X’s pioneering integrated robotic procedure has gone very well, with successful treatment of patients with both atrial and ventricular arrhythmias in a safe and effective manner.”
“We have long championed the benefits of open interoperability in electrophysiology as a means of pairing the technologies that are most appropriate for each patient,” added Dr. Tamas Selye Turok. “The full integrated use of the EnSite X with robotic stereofocus technology has worked seamlessly and we are pleased to contribute to this progress.”
“The community of clinicians leading robotics in electrophysiology has long advocated for greater integration,” said Dr. Burkhard Högel. “Integration of both systems enables me to treat patients with more complex arrhythmias. I am very pleased with this technological advance and the growing recognition that robotics plays an important role in the field of electrophysiology.”
about stereotaxicStereotaxic STXS is a pioneer and world leader in innovative surgical robots for minimally invasive endovascular intervention. Its mission is to discover, develop and deliver automated systems, tools and information solutions for the interventional laboratory. These innovations are helping clinicians provide unprecedented patient care with robotic precision and safety, expand access to minimally invasive treatment, and enhance productivity, connectivity and intelligence in the operating room. Stereotaxic technology has been used to treat more than 100,000 patients throughout the United States, Europe, Asia, and elsewhere. For more information, please visit the website www.stereotaxis.com.
This press release includes statements that may constitute “forward-looking” statements, typically containing the words “believe,” “estimate,” “project,” “expect,” or similar expressions. Forward-looking statements, by their nature, involve risks and uncertainties that may cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, the market acceptance of the Company’s products, the impact of global economic conditions on customers’ ability and willingness to purchase technology, competitive factors, and changes resulting from policy Health care, dependence on third-party vendors, timing of regulatory approvals, impact of pandemics or other disasters, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date hereof. There can be no guarantee that the Company will recognize revenue related to purchase orders and other commitments because some of these purchase orders and other commitments are subject to possibilities beyond the Company’s control and may be revised, modified, delayed or cancelled.
Stereotaxic connections:David L. Fishel President and CEO
Kimberly Perry Chief Financial Officer
314-678-6100Investors@Stereotaxis.com
Source: Stereotaxis, Inc.